Business Wire

Yokogawa Releases Dynamic Real Time Optimizer, a New Solution in the OpreX Asset Operations and Optimization Family

11.10.2019 05:00:00 EEST | Business Wire | Press release

Share

Yokogawa Electric Corporation (TOKYO:6841) announces the release of Dynamic Real Time Optimizer, a solution in the OpreXTM Asset Operations and Optimization family. Using a combination of first principles simulation and multivariable predictive control technology, the Dynamic Real Time Optimizer software helps to optimize plant operations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191010005009/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Operating window of Dynamic Real Time Optimizer (Graphic: Yokogawa Electric Corporation)

This integrated solution is based on Yokogawa’s advanced process control technologies and industry knowledge and simulation technologies developed by KBC Advanced Technologies Limited (KBC, CEO: Andrew Howell), a UK-based Yokogawa subsidiary. This solution enables plants to quickly respond to dynamically changing oil market and product market conditions and improve both productivity and profitability.

Development Background

Advanced process control systems improve product yield and reduce energy consumption by maintaining temperature, flow rate, pressure, and other process variables within a set range and keeping them as close as possible to their optimal values, even for production processes whose parameters are not easily controlled by conventional control systems. Such advanced control systems are increasingly used in facilities such as oil refineries, petrochemical plants, chemical plants, and natural gas liquefaction trains. Advanced control solutions are attracting considerable interest due to their high economic value.

Multivariable advanced control systems determine the optimal value for plant independent variables. The optimal values are calculated based on information such as feedstock quality and prices, product specifications and prices, and energy costs. In a dynamically changing market, an advanced control system optimizes the operation of a plant in real time based on changes in raw material properties, product demand, and operating conditions.

Using our advanced control technology and KBC’s industry knowledge and simulation technology, we are able to perform highly accurate dynamic real-time optimization using rigorous models, in response to dynamically changing plant and market conditions.

Features

Dynamic Real Time Optimizer calculates the optimal values for plant independent variables with a high level of accuracy and was developed based on KBC’s Petro-SIMTM process simulation platform, which includes functions for online use. This solution acquires data through online connections to control systems and plant information management systems (PIMSs) and carries out case study simulations to generate rigorous models and calculate additional inferred properties. Based on these models and operating conditions, the optimal values are calculated by applying mathematical programming*1, and implemented online by the advanced control system.

1. Multi-unit optimization based on simulations performed using rigorous models

With large-scale applications, advanced control systems need to be able to quickly process huge amounts of data. Advanced control and optimization systems must have the processing speed needed to calculate the optimal values for such large applications. However, commercially-available products today are only suitable for small- to medium-size applications and can only optimize the control of individual process units. Yokogawa’s Platform for Advanced Control and Estimation*2 is capable of high-speed processing and can collectively control large-scale applications across processes. Using this suite as its operating platform, Dynamic Real Time Optimizer achieves multi-unit optimization and control. Also, as it makes use of KBC’s simulation technologies, the Dynamic Real Time Optimizer software can obtain optimal values with high accuracy even with reaction processes that demonstrate non-linear characteristics.

2. Integrated solution with improved maintainability

The performance of advanced control and optimization systems tends to degrade over time due to changes in operating conditions, catalyst activity changes, and the aging of facilities. Dynamic Real Time Optimizer is designed to maintain advanced control performance even as a plant changes, by using an online Petro-SIM model. The structure of this solution makes it easy to maintain advanced control and optimization systems, thus enabling operators to achieve optimal performance with nearly no change in maintenance workload.

*1 A method for determining the appropriate approach within a given range of rules, using mathematical models and computers
*2 A software suite with the following functionality:
- Multivariable model predictive control (the control of multiple variables based on predictions made using models of the dynamic characteristics of plant responses)
- Soft sensing for estimating quality in real time based on temperature, flow rate, pressure, and other process values
- Customization of calculations

Major Applications

Advanced control of continuous plant processes in the oil, petrochemical, chemical, gas, and other industries

For more information

https://www.yokogawa.com/solutions/solutions/oprex/oprex-transformation/oprex-asset-operations-and-optimization/dynamic-real-time-optimizer-rt-op

About OpreX

OpreX is the comprehensive brand for Yokogawa’s industrial automation (IA) and control business. The OpreX name stands for excellence in the technologies and solutions that Yokogawa cultivates through the co-creation of value with its customers, and encompasses the entire range of Yokogawa’s IA products, services, and solutions. This brand comprises the following five categories: OpreX Transformation, OpreX Control, OpreX Measurement, OpreX Execution, and OpreX Lifecycle. Platform for Advanced Control and Estimation, an OpreX Asset Operations and Optimization family solution in the OpreX Transformation category, delivers operational excellence throughout an enterprise’s activities, from production through to supply chain optimization and risk and business management.

With this brand, Yokogawa will deliver integrated solutions that address specific needs and support its customers in their efforts to transform and grow their businesses.

About Yokogawa

Founded in 1915, Yokogawa engages in broad-ranging activities in the areas of measurement, control, and information. The industrial automation business provides vital products, services, and solutions to a diverse range of process industries including oil, chemicals, natural gas, power, iron and steel, and pulp and paper. With the life innovation business, the company aims to radically improve productivity across the pharmaceutical and food industry value chains. The test & measurement, aviation, and other businesses continue to provide essential instruments and equipment with industry-leading precision and reliability. Yokogawa co-innovates with its customers through a global network of 113 companies spanning 60 countries, generating US$3.6 billion in sales in FY2018. For more information, please visit www.yokogawa.com.

The names of corporations, organizations, products, services and logos herein are either registered trademarks or trademarks of Yokogawa Electric Corporation or their respective holders.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Yokogawa Electric Corporation
Public Relations, Integrated Communications Center
Yokogawa-pr@cs.jp.yokogawa.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 08:30:00 EEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye